ACCEL PIOGLITAZONE 30 MG
PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) : 30 MG · DIN 02303450 · ACCEL PHARMA INC
Health Canada status: CANCELLED POST MARKET
What is ACCEL PIOGLITAZONE?
ACCEL PIOGLITAZONE 30 MG contains PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) : 30 MG. It is listed in the Health Canada Drug Product Database under DIN 02303450, held by ACCEL PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 20-Mar-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ACCEL PIOGLITAZONE used for?
Monotherapy or in combination with sulfonylurea or metformin to decrease blood glucose levels in patients with type 2 diabetes mellitus (NIDDM).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02303450 |
|---|---|
| Brand name | ACCEL PIOGLITAZONE |
| Generic / active ingredient | PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) : 30 MG |
| Manufacturer | ACCEL PHARMA INC |
| Strength | 30 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A10BG03 PIOGLITAZONE |
| AHFS class | 68:20.28 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 20-Mar-2020 |
| Original market date | 2009-06-02 00:00:00 |
How is it administered?
Indicated as monotherapy or in combination with sulfonylurea or metformin. Dosage should be titrated based on HbA1c response. Re-evaluate if excessive weight gain occurs.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text (section header exists but content not in snippet).
How is it supplied?
Not explicitly detailed in the provided text (mentions 15, 30, 45 mg tablets).
Contraindications
NYHA Class I-IV heart failure; hypersensitivity; serious hepatic impairment; pregnancy; active or history of bladder cancer; uninvestigated macroscopic haematuria.
Warnings and precautions
Can cause fluid retention leading to congestive heart failure. Increased risk of bladder cancer and bone fractures (especially in females). Potential for hepatic injury.
What can be used instead?
Other Canadian products sharing ATC code A10BG03 PIOGLITAZONE. 12 of 77 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-PIOGLITAZONE | 15 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02391600 |
| ACH-PIOGLITAZONE | 30 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02339587 |
| ACH-PIOGLITAZONE | 45 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02339595 |
| ACT PIOGLITAZONE | 15 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02302861 |
| ACT PIOGLITAZONE | 30 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02302888 |
| ACT PIOGLITAZONE | 45 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02302896 |
| JAMP PIOGLITAZONE | 15 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02397307 |
| JAMP PIOGLITAZONE | 30 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02365529 |
| JAMP PIOGLITAZONE | 45 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02365537 |
| MINT-PIOGLITAZONE | 15 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02326477 |
Who else supplies PIOGLITAZONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PIOGLITAZONE appears in 134 registered pack listings across 11 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.